Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARGX-213

Other · developed by argenx

Phase 1 Most advanced trial (none active)

ARGX Developer

1 Registered trials

What is ARGX-213?

ARGX-213 is a drug given intravenously or subcutaneously.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Developer: argenx (ARGX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06968338	Phase 1	Healthy Volunteers	Completed	ARGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from argenx

Efgartigimod FDA approved Adimanebart Phase 3 ARGX-121 Phase 2 Empasiprubart Phase 3

Sources

ClinicalTrials.gov NCT06968338

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARGX page.

Follow ARGX, the company behind ARGX-213

See ARGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARGX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z